Prognostic values of S100 family members in ovarian cancer patients

Bai, Yang; Li, Liang-Dong; Li, Jun; Lu, Xin

doi:10.1186/s12885-018-5170-3

BMC Cancer

Table 2 Correlation of S100 with different clinical stages of ovarian cancer patients

From: Prognostic values of S100 family members in ovarian cancer patients

S100 family	Affymetrix IDs	No. of patients (n)		Stage	HR	95%CI	P value
S100 family	Affymetrix IDs	low exp	high exp	Stage	HR	95%CI	P value
S100A1	205334_at	65	70	I + II	0.63	0.28–1.38	0.24
S100A1	205334_at	613	607	III + IV	0.85	(0.74–0.99)	0.036
S100A2	204268_at	35	100	I + II	0.52	0.24–1.15	0.1
S100A2	204268_at	736	484	III + IV	1.12	(0.96–1.31)	0.13
S100A3	206027_at	43	92	I + II	0.58	(0.27–1.27)	0.17
S100A3	206027_at	350	870	III + IV	0.8	(0.68–0.94)	0.008
S100A4	203186_s_at	96	39	I + II	2.01	(0.91–4.47)	0.079
S100A4	203186_s_at	345	875	III + IV	1.07	(0.91–1.26)	0.42
S100A5	207763_at	65	70	I + II	0.64	(0.3–1.39)	0.26
S100A5	207763_at	914	306	III + IV	0.81	(0.68–0.97)	0.022
S100A6	217728_at	44	91	I + II	0.6	(0.28–1.31)	0.19
S100A6	217728_at	821	399	III + IV	0.88	(0.75–1.03)	0.12
S100A7	205916_at	76	59	I + II	0.34	(0.13–0.85)	0.016
S100A7	205916_at	675	545	III + IV	0.9	(0.77–1.04)	0.15
S100A7A	232170_at	22	61	I + II	0.51	(0.18–1.43)	0.19
S100A7A	232170_at	161	326	III + IV	1.26	(0.98–1.61)	0.069
S100A8	202917_s_at	57	78	I + II	0.6	(0.28–1.3)	0.19
S100A8	202917_s_at	305	915	III + IV	0.84	(0.71–0.99)	0.036
S100A9	203535_at	39	96	I + II	0.68	(0.3–1.53)	0.35
S100A9	203535_at	474	746	III + IV	0.89	(0.77–1.04)	0.13
S100A10	200872_at	63	72	I + II	0.66	(0.3–1.44)	0.29
S100A10	200872_at	799	421	III + IV	1.3	(1.11–1.51)	0.0011
S100A11	200660_at	35	100	I + II	2.17	(0.74–6.32)	0.15
S100A11	200660_at	469	751	III + IV	1.16	(1–1.35)	0.057
S100A12	205863_at	32	102	I + II	0.47	(0.22–1.03)	0.054
S100A12	205863_at	781	439	III + IV	0.82	(0.7–0.96)	0.012
S100A13	202598_at	72	63	I + II	0.23	(0.08–0.66)	0.0028
S100A13	202598_at	617	603	III + IV	0.93	(0.8–1.07)	0.31
S100A14	218677_at	99	36	I + II	0.62	(0.25–1.56)	0.31
S100A14	218677_at	654	566	III + IV	0.9	(0.78–1.05)	0.18
S100A16	227998_at	45	38	I + II	1.79	(0.64–5.04)	0.26
S100A16	227998_at	121	366	III + IV	1.37	(1.04–1.81)	0.026
S100B	209686_at	78	57	I + II	2.24	(1.02–4.92)	0.039
S100B	209686_at	530	690	III + IV	0.85	(0.74–0.99)	0.036
S100G	207885_at	55	80	I + II	0.27	(0.12–0.61)	0.00076
S100G	207885_at	373	847	III + IV	0.85	(0.73–1)	0.052
S100P	204351_at	97	38	I + II	2.38	(1.1–5.18)	0.024
S100P	204351_at	446	774	III + IV	1.24	(1.06–1.46)	0.006
S100Z	1554876_a_at	39	44	I + II	0.53	(0.19–1.48)	0.22
S100Z	1554876_a_at	129	358	III + IV	0.85	(0.66–1.09)	0.19

Notes: exp expression, OS overall survival, HR hazard ratio, CI confidence interval

Back to article page

ISSN: 1471-2407

Contact us

Submission enquiries: bmccancer@biomedcentral.com
General enquiries: ORSupport@springernature.com